Bulk Scale Formulation of Therapeutic Doses of Clinical Grade Ready-to-Use <sup>177</sup> Lu-DOTA-TATE: The Intricate Radiochemistry Aspects
Anupam Mathur(Bharat Serums and Vaccines (India)), S.S. Sachdev(Department of Atomic Energy), Sharmila Banerjee(Bhabha Atomic Research Centre), V. MANE DESHMUKH PRASHANT(Department of Atomic Energy), Ravi Seshan(Department of Atomic Energy), Sudipta Chakraborty, C. Arjun(Bhabha Atomic Research Centre), Aruna Korde(Bhabha Atomic Research Centre), Sandip Basu(Bhabha Atomic Research Centre), Barkha Karkhanis(Department of Atomic Energy), Ashutosh Dash(Bhabha Atomic Research Centre), R. Krishna Mohan(Department of Atomic Energy), K.V. Vimalnath(Bhabha Atomic Research Centre), Navin Sakhare(Department of Atomic Energy)
Cited by 8
Related Papers
Production of 177Lu for Targeted Radionuclide Therapy: Available Options
|Nuclear Medicine and Molecular Imaging|2015|375
Sustained Availability of <sup>99m</sup>Tc: Possible Paths Forward
|Journal of Nuclear Medicine|2012|140
Peptide Receptor Radionuclide Therapy: An Overview
|Cancer Biotherapy and Radiopharmaceuticals|2015|122
Targeted Radionuclide Therapy - An Overview
|Current Radiopharmaceuticals|2013|117
Development of an electrochemical 90Sr–90Y generator for separation of 90Y suitable for targeted therapy
|Nuclear Medicine and Biology|2008|99